Jazz Pharmaceuticals plc

$180.84

$0.96(-0.53%)

Jazz Pharmaceuticals plc

JAZZ

$180.84

$0.96(-0.53%)

Jazz Pharmaceuticals plc

JAZZ

NASDAQ

$180.84

$0.96(-0.53%)

Chart

Upcoming Earnings

Next report date

May 5, 2026

Report period

Q2 2026

EPS Estimate

$4.61

Revenue Estimate

$974.44M

Key stats

52-Week Range$180.84

$95.49

$198.00

Market capitalization

$11.21B

Dividend yield (indicated)

0.00%

Price to earnings Ratio (TTM)

-31.84

Basic EPS (TTM)

$-5.84

Net income (TTM)

$-356.15M

Revenue (TTM)

$4.27B

Avg. volume

1.03M

Beta (1Y)

0.23

Employees

2.80K

Market capitalization

$11.21B

Dividend yield (indicated)

0.00%

Price to earnings Ratio (TTM)

-31.84

Basic EPS (TTM)

$-5.84

Net income (TTM)

$-356.15M

Revenue (TTM)

$4.27B

Avg. volume

1.03M

Beta (1Y)

0.23

Employees

2.80K

Screener Quick Check

About Jazz Pharmaceuticals plc

Sector

Healthcare

Industry

Biotechnology

CEO

Renee D. Gala

Website

www.jazzpharma.com

Headquarters

Waterloo Exchange, Dublin, 4

IPO Date

2007-06-01

Identifiers

ISINIE00B4Q5ZN47

Description

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical...

Related Stocks

Madrigal Pharmaceuticals, Inc.

MDGL

$440.83Mkt Cap: $10.01B

Healthcare

Biotechnology

ISIN:US5588681057

Axsome Therapeutics, Inc.

AXSM

$158.23Mkt Cap: $8.09B

Healthcare

Biotechnology

ISIN:US05464T1043

Dividend Overview

This company does not pay dividends

Financials

Performance

Margin trends

Debt level and coverage

Earnings

Next: Q2 '26

Actual

Estimate

Earnings

Next: Q2 '26

Actual

Estimate

Performance

Margin trends

Debt level and coverage

Earnings

Next: Q2 '26

Actual

Estimate

Earnings

Next: Q2 '26

Actual

Estimate